A collaborative approach to combating SARS-CoV-2
A game-changing partnership between Randox Laboratories and Bosch Healthcare continues to change the testing landscape and capabilities both in laboratory and non-laboratory settings to rapidly detect SARS-CoV-2.
Providing clear and concise results, direct at the point of care, the Randox and Bosch Healthcare collaborative approach not only allows patients to take the recommended safety precautions without delay, but also provides a solution to analyse and differentiate SARS-CoV-2 from other viral respiratory diseases.
Combining science and technology, timing is of the essence in the fight against coronavirus. Together, we have combined efforts in successfully launching the Vivlaytic (pictured) – the all-in-one solution for molecular diagnostics consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection onto one small platform.
These efforts reflect a global partnership working together to deliver world-class diagnostic solutions, harnessing the power of innovation to improve health worldwide, providing an all-in-one approach minimising the spread of the virus globally.
Launched after just six weeks at the beginning of the pandemic back in March 2020, the Virial Respiratory Infection (VRI) array set the benchmark for rapidly detecting SARS-CoV-2, while simultaneously differentiating between nine other respiratory diseases, in under two and a half hours.
Randox, Bosch Healthcare Solutions and R-Biopharm are proud to offer variable analysis strategies to detect SARS-CoV-2. Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among one of the fastest PCR tests worldwide.
Since the outbreak of current pandemic, we have combined our efforts to provide a diverse range of testing solutions and approaches to meet the need of the rise in global cases. Our approaches have been utilised at all possible levels and together we open up a range of different testing strategies, with developments still underway with the upcoming release of the SARS-CoV-2 Pooling test.
The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2, offering an accelerated decentral testing approach to effectively and efficiently monitor and detect viral infection from the offset. Capable of detecting SARS-CoV-2 from up to five pooled samples simultaneously, it has a capacity to process more than 160 patient samples a day. The pooling could be done at the level of a ward, medical specialty, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools and universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.
In partnership, we continue to increase our testing capacity, enabling fully automated processing of patient samples to combat SARS-CoV-2 and COVID-19 disease.